Straumann (SAUHY) Stock Price, News & Analysis

Company Overview

Straumann Group is a Swiss company focused on implant, restorative and orthodontic dentistry. The company develops, manufactures and distributes dental implants, prosthetic components, instruments and related solutions used by dental professionals and laboratories.

Its portfolio also includes biomaterials for tissue regeneration, digital dentistry technologies and intraoral scanning solutions, as well as clear aligners offered through its ClearCorrect business. Straumann provides products and services intended to support dental restoration, tooth replacement, orthodontic treatment and digital treatment planning.

Founded in 1954 and headquartered in Basel, Switzerland, Straumann serves dental professionals, laboratories and patients through operations and distribution networks across numerous markets worldwide. The company sells its products under brands that include Straumann, Neodent, Medentika, ClearCorrect and other specialized dental brands.

Key Stats

• Today's Range: $10.89 to $11.45
• 50-Day Range: $10.50 to $12.96
• 52-Week Range: $9.44 to $13.61
• Volume: 46,678 shs
• Average Volume: 121,813 shs
• Market Capitalization: $17.40 billion
• P/E Ratio: N/A
• Dividend Yield: 0.46%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Straumann Stock Analysis - MarketRank™

Straumann scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Straumann has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 2 sell ratings.

Amount of Analyst Coverage

Straumann has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 20.00%

Earnings Growth

Earnings for Straumann are expected to grow by 20.00% in the coming year, from $0.40 to $0.48 per share.

Price to Earnings Growth Ratio

Straumann has a PEG Ratio of 1.97. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Straumann has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Straumann has been sold short.

Short Interest Ratio / Days to Cover

Straumann has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Straumann has recently increased by 669.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Straumann has a dividend yield of 0.53%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Straumann does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Straumann will have a dividend payout ratio of 12.50% next year. This indicates that Straumann will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Straumann has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Straumann this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Straumann insiders have not sold or bought any company stock.

Percentage Held by Institutions

Straumann has minimal institutional ownership at this time.

Company Calendar

• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SAUHY
• Previous Symbol: OTCMKTS:SAUHY
• CIK: 1451279
• Web: www.straumann.com
• Phone: (161) 965-1111
• Fax: 41-61-965-1001
• Employees: 11,319
• Year Founded: 1954

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 26.90
• P/E Growth: 1.97
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.14 billion
• Price / Sales: 5.46
• Cash Flow: $0.48 per share
• Price / Cash Flow: 22.43
• Book Value: $1.64 per share
• Price / Book: 6.56

Miscellaneous

• Outstanding Shares: 1,594,552,000
• Free Float: N/A
• Market Cap: $17.16 billion
• Optionable: Not Optionable
• Beta: 1.56